Sign In
Buy BHC
$4.95
-0.0600 (-1.20%)
At Close: Jun 03, 2026
Bausch's stock slides 11.8% after announcing Q2 results
07:25am, Tuesday, 09'th Aug 2022
Shares of Bausch Health Cos. Inc. BHC, +4.47% tumbled 11.8% in premarket trading on Tuesday after the company missed revenue expectations for the quarter, reported an unexpected loss, and lowered its
Drug, Biotech Stocks' Q2 Earnings on Aug 9: EXEL, BHC & More
01:14pm, Monday, 08'th Aug 2022 Zacks Investment Research
Let us look at four drug and biotech companies, EXEL, BHC, CPRX and AXSM, which are gearing up for their earnings release.
Supernus Pharmaceuticals (SUPN) Q2 Earnings Lag Estimates
09:25pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Supernus (SUPN) delivered earnings and revenue surprises of -53.33% and 2.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Bausch + Lomb beats earnings and revenue expectations; stock is up 3%
07:36am, Thursday, 04'th Aug 2022
Shares of Bausch + Lomb Corp. BLCO, +4.15% were up 3.1% in premarket trading on Thursday after the eyecare company outperformed earnings and revenue expectations in the second quarter of 2022. Bausch
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
09:35pm, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Personalis (PSNL) delivered earnings and revenue surprises of 4.76% and 21.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Bausch Health (BHC) Q2 Earnings?
04:14pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
An update on the IPO of Solta Medical and regular top-line and bottom-line numbers will grab investors' attention when Bausch Health (BHC) reports Q2 results.
Analysts Estimate Bausch Health (BHC) to Report a Decline in Earnings: What to Look Out for
02:00pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bausch Health (BHC) Dips More Than Broader Markets: What You Should Know
10:15pm, Monday, 01'st Aug 2022 Zacks Investment Research
In the latest trading session, Bausch Health (BHC) closed at $4.59, marking a -0.65% move from the previous day.
This Communication Services Stock Jumped 149%; Here Are 90 Biggest Movers From Friday
09:27am, Monday, 01'st Aug 2022 Benzinga
Gainers
Getty Images Holdings, Inc. (NYSE: GETY) shares climbed 149.1% to close at $26.15 on Friday following its merger with special-purpose acquisition company (SPAC) CC Neuberger Principal Holdin
Bausch Health: How To Price The Calamities
10:47pm, Saturday, 30'th Jul 2022
Recent court ruling has severely damaged the value of BHC. Insolvency for BHC is unlikely, primarily because they can unload their stake in BLCO and IPO Solta Medical.
Why Lottery.com Shares Are Trading Lower By 59%? 54 Stocks Moving In Friday's Mid-Day Session
05:05pm, Friday, 29'th Jul 2022 Benzinga
Gainers
Getty Images Holdings, Inc. (NYSE: GETY) shares jumped 106.7% to $21.69 after nearly 99.4% of shares were redeemed by CCNB shareholders.
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) rose 91.1% t
Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2022
02:31pm, Friday, 29'th Jul 2022 Benzinga
Upgrades
For The Carlyle Group Inc (NASDAQ:CG), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. Carlyle Group earned $1.17 in the second quarter, compared to $0.88 in the ye
Bausch (BHC) Loses 39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
01:35pm, Friday, 29'th Jul 2022 Zacks Investment Research
The heavy selling pressure might have exhausted for Bausch (BHC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in r
Bausch Receives a Mortal Blow
12:44pm, Friday, 29'th Jul 2022
Bausch Health Companies ( BHC , Financial) received a devastating body blow on Thursday when a U.S. federal court judge invalidated some key patents on its largest product Xifaxan for the treatment of
Bausch (BHC) Loses 39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:53am, Friday, 29'th Jul 2022
The heavy selling pressure might have exhausted for Bausch (BHC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in r
